
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biopharmaceutical company focused on developing therapies for dysregulated immune responses and has two promising product candidates, GRI-0621 and GRI-0803. With a current valuation that represents significant upside potential and a large market potential for IPF, GRI Bio Inc could see success in the future. Additionally, GRI Bio's financial results for the fiscal Q3 of 2025 show losses, but this is to be expected from a clinical-stage drug development company with no current revenue. The company has recently undergone multiple reverse stock splits, likely in an effort to boost its share price and attract investors.
Bears say
GRI Bio is currently experiencing a positive outlook with its recent top-line data release for GRI-0621 demonstrating positive results in its Phase 2a study for IPF. Along with this promising drug candidate, the company's second planned product, GRI-0803, also shows potential as a treatment for autoimmune disorders, a market with a large potential patient population. The company also has a strong balance sheet with enough cash to support its operations through mid-2027 and a current buy rating with an attractive 12-month price target, making it an interesting investment opportunity. However, there are potential risks associated with clinical trials and drug development, so careful consideration and monitoring of the company's progress is necessary.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares